BioWa is a U.S. subsidiary of Kyowa Kirin and the exclusive worldwide licensor of Potelligent® Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). A critical function of the immune system, ADCC enhances the ability of antibodies to kill tumor cells. With BioWa’s technology, enhancement of monoclonal antibody (Mab) potency has been shown to increase up to 100 fold both in vitro and in vivo.